Product Program year 2025 Source: CMS Open Payments

Lithostat

Drug Urological

NDC 0178-0500-01

Open in the dashboard

General payments

$732,844

111 payments

Research payments

$0

0 payments

Through program year 2025, $732,844 in general payments and $0 in research payments were reported against Lithostat (Urological).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Amount Payments
2025 General $80,264 4
2024 General $69,793 4
2023 General $53,140 32
2022 General $130,946 24
2021 General $96,453 26
2020 General $183,545 4
2019 General $118,703 17

Breakdown

Who paid General payments · program years 2019–2025
  1. Mission Pharmacal Company $732,844 111 payments
Top recipients General payments · program year 2025
  1. Donald Griffith Urology · Houston, TX $80,264 100% · 4 payments

Each share is of general payments naming this product in 2025.

Specialties paid General payments · program year 2025
  1. Urology $80,264 100% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Texas $80,264 100% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

659

Prescriptions dispensed, refills included

Drug cost

$243,465

Paid at the pharmacy, in all

Prescribers

39

With 11 or more claims of it

Medicare Part D drugs matched to Lithostat, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Lithostat Acetohydroxamic Acid Same name 39 659 $243,465

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 39 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Caroline McWilliams Internal Medicine NJ 54 $26,532 None on record
Mark White Urology NY 33 $12,798 None on record
Lawrence Lee Urology PA 29 $12,279 None on record
Jonathan Waldman Internal Medicine NY 29 $10,217 None on record
Roman Koldayev Internal Medicine NY 29 $2,987 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 39 with Patron
111 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record